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Human leukemias with chromosomal band 11q23 aber-
rations that disrupt the MLL/HRX/ALL-1 gene portend poor 
prognosis.1-13 MLL associated leukemias account for the majority 
of infant leukemia, ~10% of adult de novo leukemia and ~33% 
of therapy related acute leukemia with a balanced chromosome 
translocation. The 500 kD MLL precursor is processed by 
Taspase1 to generate mature MLLN320/C180, which orchestrates 
many aspects of biology such as embryogenesis, cell cycle, cell 
fate and stem cell maintenance. Leukemogenic MLL transloca-
tions fuse the common MLL N-terminus (~1,400 aa) in frame 
with more than 60 translocation partner genes (TPGs). Recent 
studies on MLL and MLL leukemia have greatly advanced our 
knowledge concerning the normal function of MLL and its 
deregulation in leukemogenesis. Here, we summarize the critical 
biological and pathological activities of MLL and MLL fusions, 
and discuss available models and potential therapeutic targets of 
MLL associated leukemias.
The MLL Leukemia
Human leukemias with an MLL translocation account for 
>50% of acute lymphoblastic leukemia (ALL) in infants less than 6 
mon of age and for up to 10% of both de novo acute lymphoblastic 
and acute myeloid leukemia (AML) in children and adults.14 
Furthermore, MLL translocations are also observed in ~33% of 
therapy-related myelodysplastic syndromes or acute leukemia 
patients with balanced chromosome aberrations.15 MLL stands 
for Mixed Lineage Leukemia or Myeloid Lymphoid Leukemia as 
leukemic blasts of MLL-associated leukemia commonly express 
both lymphoid and myeloid markers, and MLL translocations 
can result in both ALL and AML, respectively. The biphenotypic 
surface expression of these blasts has led to a proposal that 11q23 
abnormalities transform a hematopoietic stem/progenitor cell. 
Based on gene expression profiles, acute leukemia possessing a 
rearranged MLL exhibits a highly uniform and distinct pattern that 
clearly distinguishes them from conventional ALL or AML.16-18
The Discovery of MLL (MLL1/HRX/ALL-1)
Discovered in 1992 from cloning the gene that is disrupted in 
human 11q23 leukemias,19,20 the MLL/HRX/ALL-1 (subsequently 
assigned as MLL1) gene has since attracted scientists from various 
disciplines by its diverse functions in normal physiological and 
pathological processes.
MLL was shown to be the mammalian counterpart of Drosophila 
trithorax (trx), the founder of trithorax group (Trx-G) genes.19-24 
Genetic evidence indicated that trithorax group (Trx-G) proteins 
antagonize with polycomb group (Pc-G) proteins for proper 
homeotic gene expression through chromatin modifications.25-27 
As a transcription coactivator, MLL/trx is required for the main-
tenance of spatial patterns of Hox and HOM-C (homeotic complex) 
gene expression in vertebrates and invertebrates, respectively. 
Homozygous deficiency for MLL results in early embryonic 
lethality at embryonic day 10.5 (E10.5), while heterozygous dele-
tion of MLL incurs homeotic transformation, indicating altered 
Hox gene expression.28-30 Of note, five MLL family proteins, 
i.e., MLL1-5, have been identified but only MLL1 is involved in 
human leukemias.31
The MLL Protein
MLL orchestrates essential biological processes through its 
architecturally positioned domains that bind DNA either directly 
(sequences enriched for AT rich or non-methylated CpG) or 
indirectly (through sequence specific transcription factors such 
as E2Fs), provide interfaces for the assembly of multi-protein 
complexes, and methylate histone H3 at lysine 4. In brief, the 
MLL gene encodes a 3,969 amino acid, 500 kD protein with 
*Correspondence to: James J.D. Hsieh; Molecular Oncology; Washington 
University; St. Louis, MO 63110 USA; Email: jhsieh@dom.wustl.edu
Submitted: 02/18/09; Accepted: 05/05/09





Han Liu, Emily H.Y. Cheng and James J.D. Hsieh*
Molecular Oncology; Department of Medicine; Siteman Cancer Center; Washington University School of Medicine; St. Louis, MO USA
Abbreviations: MLL, mixed lineage leukemia or myeloid lymphoid leukemia; HRX, human trithorax; ALL-1, acute lymphoblastic 
leukemia 1; GMP, granulocytic/monocytic-restricted progenitors; CB, cord blood; AML, acute myeloid leukemia; ALL, acute lympho-
blastic leukemia; ABL, acute biphenotypic leukemia; MPD, myeloproliferative disorder; HMT, histone methyltransferase; HAT, histone 
acetyltransferase
Key words: MLL, mixed lineage leukemia, MLL fusions, 11q23 translocation, Hox, cell cycle, cell fate, taspase1
[Cancer Biology & Therapy 8:13, 1204-1211; 1 July 2009]; ©2009 Landes Bioscience
1204 Cancer Biology & Therapy 2009; Vol. 8 Issue 13
www.landesbioscience.com Cancer Biology & Therapy 1205
Roads to the MLL associated leukemia
addition to the aforementioned complexity of MLL gene regula-
tion, we and others showed that the full length MLL precursor 
(MLLFL) undergoes evolutionarily conserved site-specific prote-
olysis by Taspase1 to generate the mature MLLN320/C180 consisting 
of processed N-terminal 320 kD (MLLN320) and C-terminal 180 
kD fragments (MLLC180)38,47,48 that heterodimerize through the 
FYRN domain of MLLN320 and the FYRC plus SET domains of 
MLLC180. Taspase1-mediated cleavage of MLL is an evolutionarily 
conserved regulatory event that enables the spatiotemporal control 
of MLL downstream targets.41
The MLL Biology
The best characterized function of MLL is maintaining the 
expression of Hox clusters that dictate cell fate. The 39 mamma-
lian HoxA-D genes encode highly conserved homeobox containing 
transcription factors of which the combinatorial expression confers 
the identity of individual body segments and regulates hematopoi-
esis. Besides regulating cell fates, it is evident that MLL also 
orchestrates cell cycle progression at least through regulating 
multiple conserved domains of distinct functions: (1) three AT 
hooks, found near the N-terminus of MLL, mediate its binding 
to the minor groove of AT-rich DNA region.32 (2) a transcrip-
tion repression domain consists of a cysteine-rich CXXC DNMT 
(DNA methyltransferase1) homology region33 that can binds 
non-methylated CpG.34 (3) four PHD fingers mediate protein-
protein interactions.35 (4) a transactivation domain interacts 
with CBP/P300.36 (5) a C-terminal SET domain functions as 
a histone methyl transferase (HMT) that methylates Histone 
H3 at K4, marking transcriptionally active genes (Fig. 1A).37,38 
Over the years, a plethora of MLL interaction partners have been 
identified, providing mechanistic insights regarding how MLL 
regulates complex gene expression. MLL forms complexes with 
Menin (a tumor suppressor),39,40 cell cycle regulators (E2Fs and 
HCF-1),40-42 Pc-G proteins (BMI-1 and HPC2),33 HDACs 
(Histone Deacetylases),38 Cyp33 (a nuclear cyclophilin),33 CBP/
P300 and MOF (histone acetyltransferase),36,43 INI1/SNF5 (chro-
matin remodeling factors)44 and core components of the H3K4 
histone methyl transferase (WDR5, RbBP5 and Ash2L).45,46 In 
Figure 1. (A) Domain structure and the proteolytic maturation of the MLL protein. (B) Mechanisms of MLL fusion induced gene deregulation.
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vivo upon cre-mediated recombination. Forster et al. established 
a line of mice in which cre recombinase was regulated under the 
hematopoietic Lmo2 promoter and loxP sites were placed in the 
MLL and ENL loci.62 The Cre-loxP-mediated interchromosomal 
recombination between the MLL and ENL genes creates recip-
rocal chromosomal translocations, which rapidly causes myeloid 
tumors with rapid onset and high penetrance. The same system 
was utilized to assess the MLL-AF9 leukemia.63 The translocator 
mice models are the closest to natural chromosomal translocations 
in human cancers, as both derivative chromosomes are created 
somatically. However, this strategy requires that both targeted 
genes on the relevant mouse chromosomes are transcriptionally 
orientated into the directions of telomeres to generate the correct 
fusion following translocation. Therefore, this approach can’t apply 
to certain MLL fusions such as MLL-AF4.
Retroviral transduction of BM cells with MLL fusion genes 
followed by transplantation into syngeneic recipient mice is widely 
utilized to model MLL-associated leukemia. Such an approach 
provides quick assessments of individual MLL fusions in leukemo-
genesis and enables structure-function analysis to investigate which 
domain and what activity of MLL fusion is required for onco-
genic transformation.64,65 These studies have generated invaluable 
insights regarding the underlying mechanisms by which MLL 
fusions cause human leukemia. However, the employment of retro-
viruses likely results in uncontrolled, nonphysiological expression 
of MLL fusions. The importance of gene dosage in MLL leuke-
mogenesis has been recently demonstrated using MLL-AF9.66 
Furthermore, random insertion of retroviruses is known to facilitate 
oncogenesis through activation of an oncogene and/or inactivation 
of a tumor suppressor gene. Therefore, the retroviral strategy 
generally results in leukemias with shorter latencies compared to 
the knock-in approach. Importantly, retrovirus-mediated MLL 
fusion gene transfer into murine bone marrow cells demonstrated 
that both hematopoietic stem and more differentiated progenitor 
cells can be successfully transformed to induce leukaemia.67 Using 
a similar retroviral strategy, MLL-ENL and MLL-AF9 were shown 
to be capable of transforming primary human hematopoietic cells 
in a tumor xenograft model. In this study, MLL-ENL induces 
acute B-lymphocytic leukemia (B-ALL).68 The current mice 
models for MLL leukemias are summarised in Table 1.
Molecular Models of MLL-Associated Leukemia
The most fascinating feature of MLL associated leukemia is 
the unprecedented diversity of TPGs. To date, 104 different MLL 
rearrangements have been described and of which 64 TPGs are 
characterized at the molecular level.69 Leukemogenic 11q23 trans-
locations fuse the common MLL N-terminal 1,400 aa in-frame 
with a wide variety of fusion partners (>60) that ranges from 
nuclear factors to cytoplasmic proteins. Accumulative studies have 
now yielded major breakthroughs in our understanding of MLL 
associated leukemia.
Genetic studies on mice carrying individual MLL fusions 
reveal several fundamental aspects concerning MLL associated 
leukemia. First, MLL fusions, the products of 11q23 transloca-
tions, are responsible for the leukemogenesis.56,57,59,70,71 Second, 
the expression of cyclins and CDK inhibitors (CDKIs).41,49-51 
Interestingly, the positive and negative influence of MLL on the 
cell cycle is context dependent and involves its HMT activity. 
Furthermore, MLL itself is regulated by the cell cycle machinery. 
MLL undergoes a specialized bimodal degradation resulting in its 
biphasic expression through the cell cycle.52 This unique expres-
sion is conferred by SCFSkp2 and APCCdc20, two cell cycle specific 
E3 ligases. Importantly, deregulation of this highly choreographed 
expression through either overexpression or knockdown incurs 
cell cycle defects. The ability of MLL in coordinating cell fate 
and cell cycle regulation help to explain its essential role in both 
hematopoietic and neuronal stem cells.53-55
Mouse Models of the MLL-Associated Leukemia
To investigate the aetiology, pathogenesis, progression and 
response to treatment, several mouse models have been engineered 
to recapitulate individual MLL associated leukemias. The first 
successful MLL leukemia model in mice employed the MLL-AF9 
knock-in allele in which the AF9 sequence was integrated into 
one of the endogenous MLL allele via homologous recombination 
in mouse embryonic stem cells (ES cells), leaving the other MLL 
allele as wild-type.56 The MLL-AF9 knock-in mice developed 
an acute myeloid malignancy similar to what occurs in human 
patients with the chromosomal translocation t(9;11). Similar 
knock-in approaches were used to investigate the role of MLL-AF4 
and MLL-PTD (partial tandem duplication) in leukemia.57,58
Although the knock-in approach closely mimic the naturally 
occurring chromosomal translocations, it is limited by the fact that 
some of the knock-in alleles such as MLL-CBP result in embry-
onic lethality.59 Accordingly, mice bearing conditional MLL-CBP 
knock-in allele were generated. The conditional MLL-CBP allele 
consists of a stop cassette flanked by loxP sites that is inserted 5' 
to the CBP fusion. Before cre-mediated excision of the inserted 
stop cassette, the MLL-stop-CBP allele expresses truncated form of 
MLL. Upon excision of the stop cassette, the MLL-CBP fusion is 
specifically induced which mimics the human t(11;16) MLL-CBP 
leukemia. The induction of MLL-CBP results in an expansion of 
myeloid precursors in mice and these preleukemia mice only devel-
oped AML following the administration of sub-oncogenic doses of 
genotoxins.59 A similar strategy was used to generate a conditional 
MLL-AF4 knock-in mouse model.60 An alternative approach 
termed the invertor method was used to generate a mouse model of 
the MLL-AF4 fusion. The invertor conditional knock-in method 
depends on gene targeting of an inverted cDNA floxed cassette 
comprising a short intron, an acceptor splice site, an AF4 cDNA 
segment and a polyadenylation (pA) sequence, into the intron of 
MLL gene. The cassette is in the opposite orientation of transcrip-
tion to the target gene until inverted by Cre recombinase.61
To perfect MLL leukemia models in mice, an elegant chromo-
some translocator approach was invented. The de novo creation 
of chromosomal translocation recapitulates the naturally occur-
ring balanced translocation between MLL and its translocation 
partner gene (TPG), which is achieved by inserting one loxP site 
into the common breakpoint region of MLL and the other into 
the TPG. The MLL-TPG and TPG-MLL alleles are generated in 
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other than H3K4 methylation: (1) CBP and p300, fusion part-
ners of MLL, are histone acetyl transferases, (2) MLL-AF10 and 
MLL-ENL recruit DOT1L and promote of histone H3 lysine 79 
(H3K79) methylation on the HoxA9 promoter.78-80 Remarkably, 
other MLL fusion partners such as AF4 and AF9 also interact 
with DOT1L.81,82 (3) MLL-EEN recruits CBP and protein argi-
nine methyl transferase (PRMT1) to MLL target genes.83 Taken 
together, convincing evidence highlights deregulated histone 
modification as an important mechanism whereby MLL fusion 
induces leukemia (Fig. 1B).83
The second prevalent model concerning MLL associated 
leukemia entails the forced dimerization of the MLL N-terminus 
retained in all MLL fusions. The oligomerization domains of AF1p, 
GAS7, gephyrin and SEPT6 proteins are necessary and sufficient 
for leukemogenic transformation induced by the respective MLL 
fusion proteins.74,84,85 Dimerization of MLL-FKBP fusion protein, 
which dimerizes only in the presence of the dimerizer, AP20187, 
immortalizes hematopoietic cells and imposes a reversible block 
on myeloid differentiation.75 The transactivation and dimerization 
models are not mutually exclusive since the forced dimerization of 
MLL was proposed to initiate a transactivation complex capable 
of stimulating Hox expression in the absence of H3K4 methyla-
tion. As mice bearing MLL-lacZ developed leukemias, it has been 
fusion partners are indispensable.72 Third, fusion partners can 
be as non-specific as bacterial galactosidase (lacZ) in that mice 
bearing MLL-lacZ developed myeloid leukemias after a prolonged 
latency.72 Fourth, individual fusion partners determine the pheno-
types of resulting leukemias. For example, mice carrying MLL-AF4 
or MLL-AF9 develop lymphoid versus myeloid malignancies, 
mimicking human counterparts.57,61,70 Detailed analyses of indi-
vidual MLL fusions have established two prevalent models, 
transactivation and dimerization, emphasizing the gain-of-function 
of Hox gene expression and thus the disruption of blood lineage 
commitment.65,73-75 All of the 11q23 translocations truncate 
MLL, which result in the invariable loss of the PHD fingers, the 
Taspase1 cleavage sites, the transactivation domain, and the SET 
domain. Nevertheless, MLL fusion proteins retain the ability to 
target and activate Hox genes.
Several studies have shown that MLL fusion partners are involved 
in transcription initiation and elongation. For example, the most 
common MLL fusion partners AF4, AF9 and ENL contain tran-
scriptional activation domains, while ELL is an elongation factor 
that associates with RNA polymerase II.76 In the case of ENL, 
ELL and AFX, their transcriptional activation domain appears to 
be crucial for oncogenesis.65,73,77 The activation of target genes by 
MLL fusions can also be mediated through histone modifications 
Table 1 Mouse models of MLL associated leukemias
MLL fusion Model Phenotype Latency Reference 
   (months)
MLL-AF4 knockin lymphoid/myeloid hyperplasia, B-cell lymphoma 17 57
 conditional knockin/Mx1-Cre B-ALL, AML 4 60
 conditional knockin, invertor/Rag, Lck, CD19-Cre B-cell lymphoma 15 61
MLL-AF9 knockin AML, MPD-like myeloid leukemia 7 56, 57
 translocator/Lmo2-Cre MPD-like myeloid leukemia 9 63, 112
 retroviral AML 3 67
 retroviral/GMP AML 2 95
 retroviral/Human CB, Lin- B-ALL, AML, MLL 4 68
 retroviral/Human CB, CD34+ AML, B-ALL, ABL 2 113
MLL-ENL retroviral/Human CB, Lin- B-ALL 4 68
 translocator/Lmo2-Cre MPD-like myeloid leukemia 3 62
 translocator/Lck-Cre T-cell lymphoma, myeloid leukemia 17 112
 retroviral AML 3 64
MLL-ELL retroviral AML 5 114
MLL-AF10 retroviral AML 3 115, 116
MLL-AF1p retroviral myeloid leukemia 3 74
MLL-AFX retroviral AML 7 73, 116
MLL-FKHRL1 retroviral AML 5 116
MLL-SEPT6 retroviral MPD 4 85
MLL-GAS7 retroviral MLL 3 74, 117
MLL-EEN knockin myeloid leukemia 8 118
MLL-CBP conditional knockin myeloid hyperplasia NA 59
 retroviral myeloid leukemia 5 119
MLL-PTD knockin viable NA 58
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complex with a conserved region of the N terminus of MLL that is 
retained in all oncogenic MLL fusion proteins.99 Menin is a tumor 
suppressor whose loss of function causes human multiple endo-
crine neoplasia. Counterintuitively, Menin apparently serves as an 
essential oncogenic cofactor for MLL oncoproteins in leukemic 
transformation.100
Distinct microRNA expression profiles were identified in MLL 
leukemias.101,102 MicroRNAs (miRNAs) are short 20- to 22-nt 
RNAs that negatively regulate gene expression at the posttran-
scriptional level by base-pairing to the 3'-UTR of target messenger 
RNAs. The mir-17-92 cluster in particular, is overexpressed in 
human AMLs with MLL rearrangement.103 Additional miRNAs, 
such as mir-191, are deregulated in leukemic cell lines bearing MLL 
rearrangements.104 Moreover, overexpression of mir-196b by MLL 
fusions contributes to MLL fusion-mediated immortalization.105
Perspectives
Over the past decade, we have witnessed the remarkable strides 
made towards understanding MLL associated leukemia, which 
provide unforeseen opportunities to overcome this dreadful illness. 
Nevertheless, much needs to be learned about the normal biology 
and pathology of MLL and MLL fusions. For instance, although 
MLL fusions play an indispensable role in the MLL leukemo-
genesis, data support the necessity of additional complementary 
mutations to initiate a full MLL leukemia phenotype. The pres-
ence of a second hit has been implicated in MLL-AF4, MLL-AF9, 
MLL-CBP and MLL-lacZ knock-in models where engineered 
mice only developed leukemias after a long latency or a chal-
lenge with carcinogens such as ENU or γ-irradiation.57,59,70,72 
Indeed, several reports have identified mutations of p53, ATM, 
Ras and Flt3 in MLL leukemia patients.97,106-109 Furthermore, an 
interesting feature of human MLL leukemia is its relatively short 
latency, which implies a rapid acquisition of necessary additional 
mutations. Therefore, an underlying DNA damage checkpoint 
defect in MLL leukemia has been proposed based on an in vitro 
cell culture system. It was demonstrated that a functional activa-
tion of MLL-ENL enhances chromosomal aberrations, indicating 
a DNA damage checkpoint defect.110 Furthermore, leukemic cells 
bearing MLL-ENL are resistant to chemotherapy due to an attenu-
ated p53 response.111 The importance of checkpoint compromise, 
including but not limited to the deregulation of p53, in MLL 
fusion leukemogenesis warrants future scrutiny and validation.
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